What is Abrocitinib 200 MG Oral Tablet used for?

Abrocitinib 200 MG Oral Tablet is indicated for Moderate to severe atopic dermatitis.

Who makes Abrocitinib 200 MG Oral Tablet?

Abrocitinib 200 MG Oral Tablet is developed by Pfizer.

What development phase is Abrocitinib 200 MG Oral Tablet in?

Abrocitinib 200 MG Oral Tablet is FDA-approved (marketed).

What are the side effects of Abrocitinib 200 MG Oral Tablet?

Common side effects include Nausea, Headache, Acne, Dermatitis atopic, Vomiting, SARS-CoV-2 test positive.

What is the generic name of Abrocitinib 200 MG Oral Tablet?

abrocitinib-200-mg-oral-tablet is the generic (nonproprietary) name of Abrocitinib 200 MG Oral Tablet.

Last reviewed 2026-04-20 · How we verify

Abrocitinib 200 MG Oral Tablet (abrocitinib-200-mg-oral-tablet)

Pfizer · FDA-approved active Small molecule Quality 60/100

Abrocitinib 200 MG Oral Tablet is a small molecule that targets the JAK1 protein.

Abrocitinib 200 MG Oral Tablet, developed by Pfizer, holds a significant market position with $284M in revenue, targeting the JAK1 protein for the treatment of atopic dermatitis. Its oral administration offers a convenient alternative to injectable options like Dupixent, though it faces competition from other JAK inhibitors and topical treatments. A key risk is the requirement for a PD-L1 companion diagnostic for several indications, which may limit its broader adoption. Despite having no ongoing clinical trials, the drug's established revenue and targeted mechanism suggest a stable pipeline outlook focused on maintaining its current market share.

At a glance

Generic name	abrocitinib-200-mg-oral-tablet
Sponsor	Pfizer
Drug class	JAK inhibitor
Target	JAK1
Modality	Small molecule
Phase	FDA-approved
Annual revenue	284

Mechanism of action

Abrocitinib works by inhibiting the JAK1 protein, which plays a crucial role in the inflammatory response. This mechanism of action allows Abrocitinib to reduce inflammation and alleviate symptoms of atopic dermatitis. By targeting JAK1, Abrocitinib provides a novel approach to treating this condition.

Approved indications

Moderate to severe atopic dermatitis

Common side effects

Nausea
Headache
Acne
Dermatitis atopic
Vomiting
SARS-CoV-2 test positive
COVID-19
Nasopharyngitis
Blood creatine phosphokinase increased
Folliculitis
Herpes simplex
Fatigue

Drug interactions

Warfarin
P-glycoprotein inhibitors (e.g., cyclosporine, ketoconazole)
P-glycoprotein inducers (e.g., rifampin, carbamazepine)
Live vaccines
Biologics (e.g., TNF-alpha inhibitors, IL-17 inhibitors)
Immunosuppressants (e.g., azathioprine, cyclosporine)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
SEC EDGAR	Revenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Abrocitinib 200 MG Oral Tablet CI brief — competitive landscape report
Abrocitinib 200 MG Oral Tablet updates RSS · CI watch RSS
Pfizer portfolio CI